



# ACTAS Derma-Sifiliográficas

Full English text available at  
[www.actasdermo.org](http://www.actasdermo.org)



## PRACTICAL DERMATOLOGY

# Practical Management of Immunosuppressants in Dermatology<sup>☆</sup>



V.M. Leis-Dosil,<sup>\*</sup> I. Prats-Caelles

Sección de Dermatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, España

Received 18 December 2016; accepted 14 May 2017  
Available online 26 November 2017

### KEYWORDS

Methotrexate;  
Ciclosporin;  
Cyclophosphamide;  
Azathioprine;  
Mycophenolate;  
Immunosuppression

**Abstract** The treatment of inflammatory and autoimmune diseases is challenging because of their frequency and complexity. Treatment of these diseases is based on the suppression of the patient's immune system using corticosteroids, corticosteroid-sparing immunosuppressive agents, and biologic drugs, making an understanding of the management of immunosuppressive therapy essential. Before an immunosuppressive agent is prescribed, a study must be carried out to identify contraindications, detect latent infections, and determine the most appropriate dose. During treatment, regular monitoring is required to detect adverse effects. The clinician must be familiar with the time lag between start of treatment and onset of the immunosuppressive effect as well as the maximum recommended duration of treatment and cumulative dose for each drug. As dermatologists we are accustomed to using these immunosuppressive agents, but we should have a good knowledge of the guidelines for their use and the monitoring required in each case if we are to reduce variability and avoid potentially serious adverse effects.

© 2017 Elsevier España, S.L.U. and AEDV. All rights reserved.

### PALABRAS CLAVE

Metotrexato;  
Ciclosporina;  
Ciclofosfamida;  
Azatioprina;  
Micofenolato;  
Inmunosupresión


### Manejo práctico de inmunosupresores en dermatología

**Resumen** Las enfermedades inflamatorias y autoinmunes constituyen un desafío terapéutico por frecuencia y complejidad. Su tratamiento se basa en la inmunosupresión del paciente con glucocorticoides, inmunosupresores ahorradores de corticoides y fármacos biológicos, siendo imprescindible por tanto conocer su manejo. Cuando se va a pautar un inmunosupresor es necesario realizar un estudio previo para detectar contraindicaciones, infecciones latentes o determinar la dosis más adecuada del fármaco. Durante el tratamiento se deben realizar

<sup>☆</sup> Please cite this article as: Leis-Dosil V, Prats-Caelles I. Practical Management of Immunosuppressants in Dermatology. Actas Dermosifiliogr. 2018;109:24–34.

<sup>\*</sup> Corresponding author.

E-mail address: [vmanuel.leis@salud.madrid.org](mailto:vmanuel.leis@salud.madrid.org) (V.M. Leis-Dosil).



controles periódicos para detectar efectos secundarios. Cada fármaco tiene un tiempo de inicio de acción que es preciso conocer, así como una duración o dosis acumulada máxima recomendada. Los dermatólogos estamos habituados al uso estos fármacos inmunosupresores, pero es necesario tener claras las pautas y los controles necesarios con cada uno, para disminuir la variabilidad y evitar efectos adversos potencialmente graves.

© 2017 Elsevier España, S.L.U. y AEDV. Todos los derechos reservados.

## Introduction

Dermatologic autoimmune or inflammatory diseases are usually managed with immunosuppressants. Care must be taken to find a point of balance that attenuates the abnormal inflammatory response while causing the least possible immunosuppression.

The prescriber must be aware of each immunosuppressant's unique time to onset of action, level of acute toxicity, and dosage regimens. An intense, rapid response is sometimes warranted, but a goal in other circumstances might be a treatment that can be followed over the long term.

This review deals with classic immunosuppressants. Neither glucocorticoids nor biologics will be discussed.

## Pretreatment Tests and Vaccinations

Before suppressing a patient's immune response, information is required for ruling out contraindications, tailoring the dosage, and planning measures to reduce inherent risk.

Certain laboratory tests are needed for prescribing any of these drugs, but particular immunosuppressants also have specific requirements<sup>1</sup> (Table 1).

Because vaccination coverage should be on record for all patients, serology is included in the test battery.<sup>2-5</sup> If the patient's clinical condition permits, required vaccinations or booster doses should be scheduled at least 2 weeks before immunosuppressant therapy starts. If vaccination is not feasible beforehand, it should not be undertaken until at least 3 months after treatment stops given that live virus vaccines carry the risk of infection, and immunization may not be achieved if inactivated viruses are used.

Vaccination against varicella should be tailored to the individual. If a pediatric vaccination schedule must be followed, immunosuppressants should be interrupted 2 weeks before vaccination and not restarted until 2 weeks afterwards.<sup>6</sup>

Two types of pneumococcal vaccines are available: the 23-valent polysaccharide (PPSV23) and 13-valent conjugate (PCV13) versions. Spanish health authorities stipulate a sequential vaccination schedule for patients on

**Table 1** Complementary Tests to Order Before Starting Immunosuppressant Therapy.

Methotrexate	Ciclosporin	Azathioprine	Mycophenolate Mofetil and Mycophenolate Sodium	Cyclophosphamide
Complete blood count, including differential white blood cell counts Biochemistry, including glucose, ion concentrations, kidney function, liver function (transaminase, alkaline phosphatase, bilirubin, albumin), lipids, uric acid Serology for HBV, HBC, and HIV Full vaccination coverage Tuberculosis screening (Mantoux test or quantitative interferon gamma release assay) Pregnancy test in women of childbearing age				
Contraindicated if total bilirubin concentration is > 5 mg/dL Urinalysis Chest x-ray P3NP level	Estimated GFR to determine renal function and adjust dosage. Blood pressure	TPMT level		Chest x-ray (consider) Urinalysis. Rule out adrenal insufficiency (baseline cortisol and ACTH levels, stimulation test to measure cortisol before and after injection of 250 µg of ACTH). Spermogram and sperm banking prior to treatment.

Abbreviations: ACTH, adrenocorticotrophic hormone; GFR, glomerular filtration rate; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; P3NP, procollagen type III N-terminal peptide; TPMT, thiopurine methyltransferase.

**Table 2** Basic Features of Immunosuppressants to Know When Selecting a Therapy.

	Methotrexate	Ciclosporin	Azathioprine	Mycophenolate Mofetil and Mycophenolate Sodium	Cyclophosphamide
Dermatologic indications in the summary of product characteristics	Psoriasis.	Psoriasis. Atopic dermatitis.	Systemic lupus erythematosus. Dermatomyositis. Pemphigus vulgaris. Pyoderma gangrenosum.	None.	''Life-threatening'' autoimmune diseases.
Recommended dosage	From 5 to a maximum of 25 mg/wk.	2.5–5 mg/kg/d.	2–2.5 mg/kg/d (adjust for TPMT level). Maximum dosage 200 mg/d.	Mycophenolate mofetil: 1–2 g/d in 2 doses. Mycophenolate sodium: 1080–1440 mg/d.	Oral: 1–2 mg/kg/d; maximum, 2.5 mg/kg/d. IV: 500–1000 mg/m <sup>2</sup> of body surface per month.
Onset of action	Slow, 4–8 wk. Wait 12 wk before declaring treatment failure.	Rapid, 2–4 wk.	May take months.	Most responders improve in 4 wk; some need 3 mo.	Rapid, from 2 to 16 wk, around 5 wk on average.
Maximum duration of treatment recommended	Assess liver toxicity at cumulative doses of 1500 mg.	1 y	According to course of disease. Carcinogenic risk after 10 y.	According to tolerance and response.	Significant cumulative toxicity, but can be maintained.

Abbreviations: IV, intravenous; TPMT, thiopurine methyltransferase.

Source: Summaries of product characteristics posted by the Spanish Agency for Medicines and Health Products. Available from <https://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=detalleForm>

immunosuppressants.<sup>7</sup> The schedule starts with a dose of PCV13 before treatment and is followed by a dose of PPSV23 at least 8 weeks later. If the patient is already under treatment, these criteria should be applied when the first consultation takes place. A booster dose of PPSV23 should be given at 5 years.

Patients on immunosuppressants should receive the same influenza vaccination produced for the general population every year.<sup>8</sup>

Certain factors affect the choice of one immunosuppressant drug (Table 2) over another:

- whether or not the patient has a medical history that includes a contraindication for a particular immunosuppressant or new testing reveals such a contraindication,
- whether or not the drug's summary of product characteristics includes the patient's disease,<sup>9–13</sup>
- whether or not an intense, rapid response is required,
- or alternatively, whether the prescriber seeks a maintenance of effect over a long course of treatment.

### Practical Aspects of Immunosuppressant Therapy

Once an immunosuppressant is selected, it must be fully understood if we are to achieve the best results for our patient. For practical purposes we will analyze the main

aspects relevant to managing the immunosuppressants most often prescribed by dermatologists (Tables 3–7).

### Methotrexate

Methotrexate, an antimetabolite analog of folic acid, inhibits dihydrofolate reductase. It is unquestionably one of the most often prescribed immunosuppressants in dermatology.<sup>14</sup>

Although psoriasis is the only indication listed in the product summary,<sup>13,15,16</sup> many studies have supported this drug's use in other conditions.<sup>17</sup> Some examples are autoimmune bullous diseases<sup>18</sup>; severe adult atopic dermatitis<sup>19</sup>; alopecia areata<sup>20</sup>; chronic urticaria<sup>21</sup>; cutaneous lupus erythematosus<sup>22,23</sup>; sarcoidosis, scleroderma, lymphomatoid papulosis and other lymphoproliferative disorders<sup>17,24</sup>; and keratoacanthomas.<sup>25</sup>

Methotrexate is available in tablets of 2.5 mg and syringes prefilled with doses ranging from 7.5 to 30 mg (Table 3). Oral administration is much more economical than parenteral injection and the bioequivalence is similar, at least up to a weekly dose of 17.5 mg.<sup>14,16</sup> However, gastrointestinal symptoms are common with oral intake, and injections are therefore recommended when the dose exceeds 15 mg to prevent digestive intolerance. Parenteral administration is also advisable when the patient is at risk of confusing doses or adherence is poor.<sup>26</sup>

The patient must be told that the drug is taken or injected once a week, not daily, if serious side effects are to be

**Table 3** Practical Aspects of Treatment With Methotrexate.

Pharmaceutical forms	2.5 mg tablets. Prefilled syringes (7.5, 10, 15, 20, 25, and 30 mg).
Posology	Initial dosing: 7.5–15 mg/wk. Schedule a specific day of the week to avoid confusion. Gradually increase the dose as needed. Avoid exceeding 20 mg/wk. Supplement with folic acid, 5–15 mg/wk taken 24–48 h after the methotrexate dose.
Monitoring during treatment	Complete blood count, including ion concentration and kidney and liver function profiles. Increase the dose after 1 wk and then after 2, 4, 6, 10, 14, and 18 wk; then after 3 mo. PIIINP every 3 mo. Elastography (FibroScan) if an abnormal PIIINP concentration is found more than twice.
Contraindications	Pregnancy (and men should not father a child until 3 mo after interrupting treatment). Severe liver disease. Marked cytopenia.
Concurrent drugs to avoid	Live or attenuated virus vaccines, cotrimoxazole, phenytoin, ciclosporin, azathioprine, NSAIDs.
Indications for discontinuing therapy or adjusting the dose	Pregnancy. Significant, sustained increase in PIIINP concentration. Sustained MCV increase that does not resolve with folic acid.

Abbreviations: MCV, mean corpuscular volume; NSAID, nonsteroidal anti-inflammatory drug; PIIINP, procollagen type III N-terminal peptide.

**Table 4** Practical Aspects of Treatment With Ciclosporin.

Pharmaceutical forms	Capsules of 25, 50, and 100 mg. Oral solution, 100 mg/mL.
Posology	Initial dosing: 2.5–3.5 mg/kg/d (calculated based on ideal weight, not actual weight, to avoid overdosing). Maintenance at the lowest effective dose. Do not exceed 5 mg/kg/d.
Monitoring during treatment	Blood pressure weekly, always under the same conditions. The patient should record readings and bring them to medical visits. Laboratory tests: Complete blood count, including ion concentrations, kidney and liver function profiles, uric acid level, and urinalysis. Repeat every 2 wk for the first 3 mo, then monthly. Drug levels can be measured if interactions or poor adherence is suspected.
Contraindications	Active infections. Neoplasms (rule out basal cell carcinoma). Uncontrolled arterial hypertension. No not use phototherapy, due to increased risk of tumors. Kidney failure (monitor renal function). Liver failure, cirrhosis (avoid ciclosporin or use low doses).
Concurrent drugs to avoid	Numerous interactions with drugs metabolized by cytochrome P450 and CYP34A
Indications for discontinuing therapy or adjusting the dose	After 1 y of therapy (recommended). Hypertension detected on 2 measurements after which the dosage is lowered 25%; if there is no improvement, add an antihypertensive medication (a dihydropyridine calcium channel blocker, an ACE inhibitor, or an angiotensin-II receptor blocker); if no improvement, discontinue ciclosporin. Kidney toxicity: if creatinine clearance is impaired according to 2 measurements within 2 wk, lower the dose 25%; if there is improvement, maintain ciclosporin at the lower dose; if no improvement, discontinue.

Abbreviations: ACE, angiotensin converting enzyme.

avoided.<sup>17,26</sup> It is good practice to establish a particular time each week that takes into consideration that the dose will be followed by days of discomfort and that samples for laboratory tests must be collected the day before dosing, as long as possible before the drug is actually taken. The entire oral

dose can be ingested at once or in 2 or 3 fractions separated by 12 hours.<sup>15</sup>

A test dose is not currently considered necessary.<sup>27</sup> A starting dosage of 7.5 to 15 mg/wk should be given and gradually increased until the response is satisfactory. Increases

**Table 5** Practical Aspects of Treatment With Azathioprine.

Pharmaceutical forms	Tablets of 50 mg.
Posology	0.5–3 mg/kg/d. Adjust for TPMT activity. Start at a low dose and increase according to tolerance and response. If TPMT testing is unavailable, start with a low dose (50 mg/d) and gradually increase with strict follow-up (complete blood count). If MCV increases less than 3 fL in 3 mo, the dosage can be increased 0.5 mg/kg/d. If MCV increases > 8 fL, lower the dosage 0.5 mg/kg/d and repeat testing, including for folic acid and vitamin B <sub>12</sub> . Divide the daily dose in 2 fractions to improve gastrointestinal tolerance.
Monitoring during treatment	Complete blood count, kidney function, liver function at 1, 2, 3, 4, 6, 8, 12, 16, and 20 wk. Then, every 3 mo.
Contraindications	Allergy to azathioprine or 6-mercaptopurine. Neoplasms (current). TPMT absent or < 5 IU/mL
Concurrent drugs to avoid	Mycophenolate mofetil, mycophenolate sodium. Live or attenuated virus vaccines. Allopurinol. Sulfasalazine. Cotrimoxazole. ACE inhibitors.
Indications for discontinuing therapy or adjusting the dose	Breastfeeding. Assess risks-benefits during pregnancy. Hypersensitivity reaction. Pancreatitis. Hepatotoxicity. Myelotoxicity.

Abbreviations: ACE, angiotensin converting enzyme; MCV, mean corpuscular volume; TPMT, thiopurine methyltransferase.

**Table 6** Practical Aspects of Treatment With Mycophenolate Mofetil and Mycophenolate Sodium.

Pharmaceutical forms	MPS: enteric-coated tablets of 180 and 360 mg. MMF: capsules of 250 mg, coated tablets of 500 mg, powder for oral suspension of 1 g/5 mL, vials of 500 mg.
Posology	MPS: 720 mg/12 h. MMF: start with 250–500 mg/12 h and increase every wk until a dosage of 1 g/12 h can be maintained. Never administer a bolus dose intravenously. Capsules and tablets should be swallowed whole with a glass of water. MMF can be taken with or without food. MPS can also be ingested with or without food, but once a habit is started it should be continued.
Monitoring during treatment	Complete blood count every 2 wk in the first month, then monthly for 3 mo, then every 2 mo.
Contraindications	Pregnancy, breastfeeding, drug allergy.
Concurrent drugs to avoid	Azathioprine, ciclosporin, live virus and attenuated virus vaccines, aciclovir, colestyramine, tacrolimus, rifampicin, antacids.
Indications for discontinuing therapy or adjusting the dose	Severe leukopenia (<1300 cells/mL)

Abbreviations: MMF, mycophenolate mofetil; MPS, mycophenolate sodium.

of 2.5 to 5 mg can be tried every 4 to 6 weeks.<sup>17,19</sup> Responders usually improve at 4 weeks, but we have waited up to 12 weeks before deciding that treatment has failed. A regimen of 15 mg/wk is usually effective. The approach should be reviewed if 25 mg/wk is exceeded.<sup>26</sup>

The strategy to follow is similar in psoriasis and other diseases. In autoimmune bullous diseases, for example, certain patients are nonresponders (13% in pemphigus vulgaris, 4% in bullous pemphigoid), and no data on predictors of failure are available. On the other hand, mortality due to serious infection is considerable (3.7% in pemphigus vulgaris, 2.5% in bullous pemphigoid). Nonetheless methotrexate therapy remains a good corticosteroid-sparing strategy.<sup>18</sup>

Methotrexate should be accompanied by folic or folinic acid supplementation, which significantly reduces adverse effects on the liver and nonsignificantly improves effects

on mucosal, gastrointestinal and blood tissues but does not prevent the development of pulmonary fibrosis.<sup>26,28</sup> Some studies consider supplementation to be contraindicated in the interest of efficacy, but a reduction in methotrexate's effect with folic acid is fairly unlikely<sup>28</sup> because the 2 drugs promote the anti-inflammatory action of adenosine through different mechanisms.<sup>16</sup> Folic acid and folinic acid do not appear to differ in effectiveness, and the former is less costly. Dosage regimens are debated. They vary from 5 to 30 mg/wk unless other conditions requiring folic or folinic acid supplementation are present, in which case 5 mg/week taken 24 to 48 hours after the methotrexate dose should be sufficient.<sup>26</sup>

One of the main adverse effects of methotrexate is liver fibrosis. One systematic review found that the risk for fibrosis increased 22% in patients with methotrexate-

**Table 7** Practical Aspects of Treatment With Cyclophosphamide.

Pharmaceutical forms	Tablets of 50 mg. Vials of 200 and 1000 mg in solution.
Posology	Oral: 50–100 mg/d; can be increased to 2 mg/kg/d in severe cases. The tablet must be taken whole, neither chewed nor crushed. To minimize side effects, take in single doses in the morning and drink plenty of liquids (3 L/d). Empty bladder before going to sleep. Take antiemetics if necessary. Intravenous pulse therapy: starting dose, 500 mg/m <sup>2</sup> ; then 750 mg/m <sup>2</sup> ; then, if tolerated, 1000 mg/m <sup>2</sup> . Administer intravenous fluids in abundance. Prescribe antiemetics, possibly before cyclophosphamide. Evaluate possible use of intravenous infusion.
Monitoring during treatment	<i>Oral therapy</i> Complete blood count every 7–14 d for 1 mo on initiating treatment and after any dosage changes. Then every 1–3 mo. Adjust dosage to maintain white blood cell count > 4000 cells/mL. Urinalysis every 1–3 mo. Urine cytology 1–2 times/y. Cytoscopy if blood in urine or abnormal cytology findings. Liver workup every 3 mo. Pregnancy test. <i>Intravenous pulse therapy:</i> Complete blood count immediately after an infusion and 10–14 d later.
Contraindications	Absolute: Pregnancy and breastfeeding, drug allergy, myelosuppression, history of bladder cancer. Relative: active infection, liver or kidney failure.
Concurrent drugs to avoid	Succinylcholine, anticholinergic agents, allopurinol, busulfan, chlorpromazine, ciprofloxacin, fluconazole, thiotepa
Indications for discontinuing therapy or adjusting the dose	Bladder cancer, acute cardiotoxicity.

treated psoriasis; however, risk was not significantly related to duration of therapy or cumulative dose.<sup>29</sup> The authors therefore concluded that fibrosis develops only in a certain subgroup of patients whose characteristics could not be determined due to the low quality of evidence provided by the studies reviewed. It is likely that comorbid conditions such as obesity or alcohol intake exacerbate risk in some. A noninvasive means for detecting fibrosis without resorting to liver biopsy is required. The most widely studied approaches are the measurement of biomarkers (eg, procollagen type III N-terminal peptide<sup>30</sup>) and the use of imaging techniques such as elastography (eg, FibroScan). One meta-analysis showed that these 2 techniques applied individually have low discriminatory power in screening.<sup>31</sup> However, combining various biomarkers (eg, in the enhanced liver fibrosis panel) or biomarkers and imaging may be more useful.

## Ciclosporin

Ciclosporin is a calcineurin inhibitor that acts on T cells. The summary of product characteristics for this drug lists psoriasis and atopic dermatitis as the dermatologic indications. However, ciclosporin has been used to effectively treat Stevens–Johnson syndrome,<sup>32</sup> lichen planus and lichen planopilaris,<sup>33</sup> pyoderma gangrenosum, chronic urticaria,

autoimmune blistering diseases, suppurative hidradenitis, and more.<sup>34,35</sup>

The great advantage of ciclosporin is its rapid onset of action. Good control of disease can be achieved in a few months with a short treatment cycle.

Dose regimens range from 2.5 to 5 mg/kg/d<sup>36</sup> (Table 4). Although ciclosporin is lipophilic, it is important to remember that distribution is mainly through lean tissues. Therefore, when the real weight of obese patients is used to calculate the dosage, the concentration of the circulating drug will be elevated and there is risk of toxicity. Consequently, the dose should be calculated based on the patient's ideal weight.<sup>37</sup>

The daily dose is usually divided into 2 fractions. Taking ciclosporin before food intake has been shown to facilitate absorption, allow for lower doses and favor more even, predictable pharmacokinetics. Ciclosporin should therefore be taken before breakfast and before the evening meal.<sup>38</sup>

It is generally not recommended to prolong treatment beyond 1 year because long treatment cycles carry greater risk of toxicity. However, strategies that allow treatment to be maintained as long as possible have been explored. The 2 usual approaches, particularly in psoriasis, involve rotations and combinations that allow for lower daily doses. Weekend pulse therapy is another possibility once a conventional regimen has achieved control of disease. This regimen consists



of prescribing a maintenance dose of up to 5 mg/kg/d for 2 consecutive days per week and resting for the rest of the week. In psoriasis the efficacy of this strategy is similar to that of continuous therapy even though the mean daily dose is significantly lower.<sup>39</sup> This regimen has produced promising results in pediatric patients with severe atopic dermatitis, enabling long-term therapy that avoids relapses<sup>40</sup> with less toxicity and a lower cumulative dose.

Two of the main adverse effects that require dosage adjustment are kidney damage and arterial hypertension. If the creatinine level increases 30% over baseline on 2 consecutive reports 2 weeks apart, the dose should be lowered 25%. Hypertension would indicate the same dose adjustment. If the creatinine level or blood pressure returns to normal, ciclosporin treatment can continue at the lower dose. However, if these 2 variables remain elevated or continue to rise after 4 weeks on the lower dose of ciclosporin, the drug should be discontinued.<sup>36,37</sup>

Ciclosporin treatment can generally be suspended immediately without a rebound effect, although gradual weaning can lengthen the period of resolution before the next flare-up. Indications for discontinuing treatment are the failure to achieve good control of disease by 12 weeks, the development of severe adverse effects (neoplasms, infections), or a failure of blood pressure or creatinine levels to return to normal after a dose reduction. Cyclosporin should ideally be halted during pregnancy, unless symptoms make treatment necessary and there are no safer alternatives. In case treatment continues, the pregnancy should be considered high risk and followed closely. Treatment interruptions may be necessary in children so that vaccinations can be scheduled.

## Azathioprine

Azathioprine is indicated for inflammatory diseases and the prevention of solid organ transplant rejection. This prodrug is promptly metabolized to 6-mercaptopurine, which is activated along various metabolic pathways by enzymes that form thioguanine nucleotides that are then incorporated into DNA, accounting for the drug's biological effects.<sup>41,42</sup>

Thiopurine methyltransferase (TPMT) is an enzyme that methylates various intermediate products, many of them inactive. In a small population percentage (0.3%) of individuals who are homozygous for one of the alleles associated with low or no activity, azathioprine would be contraindicated; in the 9% to 11% of heterozygotic individuals, activity is intermediate; finally, 89% to 91% of the population are homozygotic for an allele associated with high activity.<sup>41,43-45</sup> Patients with high TPMT activity require higher doses of azathioprine to reach therapeutic levels than those with lower TPMT activity. However, low TPMT activity carries a higher risk of myelosuppression under treatment. Measurement of TPMT has been shown to be useful for establishing the safest and most effective dosage for each patient in both adults and children.<sup>43,46-48</sup> Tests for TPMT are used increasingly often, and their cost has become more competitive. However, if testing is unavailable, azathioprine therapy can begin with low doses that are increased gradually under strict monitoring to detect early markers of myelosuppression.

Other adverse effects, whether idiosyncratic or dose dependent, bear no relation to TPMT activity and may appear even when enzyme levels remain normal.<sup>41,47,49,50</sup> There has even been a reported case of treated alopecia areata in which bone marrow suppression developed in the context of normal TPMT concentrations.<sup>51</sup> A recent meta-analysis identified a significant association between the presence of TPMT gene polymorphisms and general adverse effects of azathioprine therapy, bone marrow toxicity and gastric intolerance, although no association with hepatotoxicity was found.<sup>52</sup>

The measurement and genotyping of glutathione-S-transferase have proven useful for assessing the risk of leukopenia in patients with inflammatory bowel disease, especially in oriental populations; however, it remains to be determined whether this marker is related to any other adverse effects of azathioprine therapy.<sup>53</sup>

Patients mainly complain of bowel discomfort, with nausea, vomiting, diarrhea or abdominal pain, and these symptoms are the usual reason for discontinuing treatment. To avoid these adverse effects, doses can be fractioned and taken with food.<sup>45</sup>

If gastrointestinal discomfort is severe or prolonged, hepatotoxicity, hypersensitivity, and pancreatitis must be ruled out.<sup>50</sup> In pancreatitis, symptoms and laboratory results usually improve rapidly when the drug is discontinued.

The carcinogenic potential of azathioprine therapy is one of the greatest concerns. The risk is difficult to calculate and varies greatly between patient series. In addition to immunosuppression, azathioprine itself has been shown to cause photosensitivity, specifically in the UV-A spectrum; sun exposure therefore has a synergistic carcinogenic effect in azathioprine-treated patients.<sup>42</sup> Additional risk factors for developing skin cancer in these patients are prolonged treatment, high-dose regimens, and a fair-skinned phototype.<sup>50</sup> In addition to skin cancer, there is risk of lymphoma, and cases of Kaposi's angiosarcoma and renal cell carcinoma have been described.<sup>54</sup>

Hypersensitivity to azathioprine can cause a variety of symptoms: fever, joint and muscle pain, nausea, hepatitis, interstitial nephritis, kidney failure, maculopapular rash, and panniculitis. A diagnostic challenge test can trigger a severe reaction, so it should be done in a hospital where the means for cardiopulmonary resuscitation are at hand. In such cases, 6-mercaptopurine therapy would be a better tolerated alternative.<sup>41</sup>

The risk of infection also increases. Viral warts, molluscum contagiosum, folliculitis, and impetigo are common in treated children.<sup>55</sup>

## Mycophenolate Mofetil and Mycophenolate Sodium Salt

The selective, reversible inhibition of inosine monophosphate dehydrogenase type 2 by mycophenolate mofetil (MMF) or mycophenolate sodium (MPS) interferes with the purine synthesis pathway of T and B cells, but not other cells.<sup>56,57</sup> MMF is a prodrug that becomes mycophenolic acid once digested. The MPS salt is sold in an enteric-coated form.<sup>58</sup>

MMF or MPS therapy is indicated in heart, liver, or kidney transplanted patients to prevent acute rejection. No approved dermatologic uses are listed in the product summaries.<sup>12</sup>

However, the use of these drugs has been explored in various inflammatory diseases because liver and kidney toxicity is higher with alternative immunosuppressants.

Onset of action, which is slower than in glucocorticoid or ciclosporin treatment, takes at least 1 month and sometimes 3 to 4 months. This therapeutic option, therefore, is for maintenance of effect,<sup>58</sup> either by itself or as a corticosteroid-sparing strategy.

Good outcomes have been reported in pyoderma gangrenosum<sup>58</sup> and severe atopic dermatitis with both MMF<sup>56</sup> and MPS<sup>59,60</sup> in both adults and children.<sup>61</sup> Positive results have also been reported in pemphigus vulgaris,<sup>62</sup> collagenosis,<sup>63,64</sup> chronic idiopathic urticaria,<sup>65</sup> and lichen planus and sarcoidosis.<sup>64</sup> The results in psoriasis have been less positive,<sup>66</sup> although one randomized clinical trial found that efficacy was statistically similar to that of methotrexate.<sup>67</sup> Evidence generally comes from single case reports or case series. Hardly any high quality randomized clinical trials have been published.

Immunosuppressant doses of these drugs vary in inflammatory diseases; doses of 500 mg to 1 g of MMF are given every 12 hours (or 720 mg of MPS every 12 hours). If a daily dose of 2 g of MMF is reached without response, plasma levels of mycophenolic acid should be measured to rule out poor adherence or decide whether to increase the dose if absorption is low.<sup>68</sup> Plasma levels vary greatly between patients and, curiously, between diseases. Mycophenolic acid plasma trough level has been shown to be a poor predictor of the effectiveness and safety of MMF therapy.

A great advantage of MMF over other immunosuppressants is its good tolerance and safety profile, particularly with regard to renal toxicity, hepatotoxicity, and neurotoxicity.

The most commonly reported adverse effects (in 12%–36%) involve the digestive system<sup>63</sup> and include diarrhea, nausea, vomiting, abdominal pain, and soft stools. These effects are dose dependent and rarely oblige discontinuance of treatment. Transaminase levels rise in some patients, but no clinical impact or clear hepatotoxicity has been reported. Enteric-coated MPS is better tolerated.

Leukopenia is observed more often than anemia or thrombocytopenia, and again, the relationship is dose dependant. At dosages of 3 g/d, this adverse effect develops in 34% of patients.<sup>64</sup> If neutrophil counts fall below 1300 cells/mL, discontinuance is indicated. Red cell dysplasia has been reported, particularly in transplanted patients.<sup>68</sup> These hematologic effects usually improve quickly when the drug is discontinued or the dose is reduced.

Urinary tract symptoms (dysuria, urgency, frequent urination, sterile pyuria, or hematuria) are not unusual, especially at the beginning of treatment. They usually improve after a year.

Conclusions about the risk of infection and neoplasia vary greatly in the literature. Published studies are difficult to compare, given that transplanted patients tend to receive higher doses and take more concurrent immunosuppressants than patients who have inflammatory diseases.

## Cyclophosphamide

Cyclophosphamide is an alkylating agent that interferes with DNA replication by attaching an alkyl group to the guanine base,<sup>69</sup> causing cell death. The drug targets T cells and, to a lesser degree, B cells.<sup>70</sup> The usual oral dosage is 1 to 2 mg/kg/d; the intravenous dosage is 500–1000 mg/m<sup>2</sup> of body surface every month.

Because this potent drug has adverse effects, it is reserved for particularly severe cases. Dermatologic indications are autoimmune bullous diseases (especially pemphigus vulgaris and pemphigus foliaceus), autoimmune systemic vasculitis; severe cutaneous lupus erythematosus; cutaneous manifestations of systemic sclerosis; and cutaneous T-cell lymphoma.<sup>71,72</sup>

A higher cumulative daily dose increases the risk of toxicity in oral administration. Therefore, different therapeutic regimens have attempted to minimize that risk. Among the strategies tried are monthly intravenous infusions either alone or combined with low-dose oral therapy, and a single immunoablative high dose without stem-cell rescue. The efficacy of these alternative approaches seems to differ little from that of daily oral doses.<sup>70–76</sup> Intravenous pulse therapy, however, leads to a lower cumulative dose and seems to be safer.<sup>77</sup>

Digestive symptoms such as nausea, vomiting, diarrhea, and stomatitis are common. Nausea is reported more in pulse therapy than oral treatment. Antiemetic prophylaxis is recommended.

Myelosuppression is an acute, dose-dependent adverse effect that usually presents with leukopenia. Monitoring is required to adjust the dose to keep the white blood cell count above 3500 to 4000 cells/mL. If the neutrophil count falls to dangerously low levels, granulocyte-colony-stimulating factors may have to be given.<sup>77</sup> Treatment with cotrimoxazole or dapsone is recommended to guard against *Pneumocystis jirovecii* infection.<sup>73</sup> Between 9% and 15% of patients had to be hospitalized for severe herpes zoster infection in some series.<sup>71</sup> As in the context of other immunosuppressant therapies, pneumococcus as well as regular influenza vaccinations are indicated.

Hemorrhagic cystitis is a typical side effect of cyclophosphamide therapy. The incidence ranges from 8% to 41%, depending on dose, and oral intake seems to be associated with greater risk than pulse treatments. This complication seems to be caused by urinary secretion of a metabolite (acrolein) that irritates the urothelium. Preventive measures include drinking plenty of liquids, not taking the drug at night, and voiding the bladder before going to bed so that acrolein does not remain in contact with the mucosal tissue all night. Intravenous pulse infusion should be accompanied by intense fluid therapy to force diuresis. Adjuvant treatment with sodium 2-mercaptoethane sulfonate (Mesna), which binds to and deactivates acrolein, is also an option. This drug is given immediately after and again 4 and 8 hours after cyclophosphamide, and each infusion should contain a dose that is 20% of the cyclophosphamide dose. In other words, after a dose of 1000 mg of cyclophosphamide, the patient should receive 3 doses containing 200 mg of Mesna each.



The other adverse effects of cyclophosphamide involve gonadal toxicity. Oral intake in particular seems to lead to premature ovarian failure, azoospermia, menstrual irregularity, and potentially irreversible infertility. The use of testosterone in men and gonadotropin-releasing hormone analogs in women is a subject of debate. Cyclophosphamide should therefore be avoided in patients of reproductive age. If it must be prescribed, the patient should be referred for reproductive counseling to assess the advisability of cryopreservation.

## Conflicts of Interest

The authors declare that they have no conflicts of interest.

## References

- Cotes ME, Swerlick RA. Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus. *Dermatol Ther.* 2013;26:120–34.
- Grupo de trabajo de vacunación de adultos de la ponencia de programas y registro de vacunaciones. Vacunación en adultos. Madrid: Ministerio de Sanidad y Consumo; 2004.
- Eibl MM, Wolf HM. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. *Immunotherapy.* 2015;7:1273–92.
- Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. *Clin Infect Dis.* 2014;58:309–18.
- Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization: Recommendations of the advisory Committee on Immunization Practices (ACIP). *Pediatrics.* 2007;119:1008.
- Limia-Sánchez A, Cañellas-Llabrés S. Revisión de las recomendaciones de vacunación frente a varicela en grupos de riesgo. Ponencia de Programas y Registro de Vacunaciones. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2015.
- Recomendaciones de Programas de Vacunaciones. Vacunación frente a neumococo en grupos de riesgo. 2015 [cited 2016 Dec 11]. Available from: <https://www.msssi.gob.es/eu/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Neumococo-Gruposriesgo.pdf>
- Souto Castro C. La respuesta del personal sanitario de España durante las campañas de vacunación antigripal. 2014 [cited 2016 Dec 11]; Available from: <https://addi.ehu.es/handle/10810/13031>
- Ficha Técnica Imurel 50mg comprimidos recubiertos con película. [internet] 2016 [cited 2016 Dec 15]. Disponible en: [https://www.aemps.gob.es/cima/dochtml/ft/50043/FichaTecnica\\_50043.html](https://www.aemps.gob.es/cima/dochtml/ft/50043/FichaTecnica_50043.html)
- Ficha Técnica Ciclofosfamida Sandoz 500mg polvo para solución inyectable y para perfusión. [internet] 2015 [cited 2016 Dec 15]. Available from: [https://www.aemps.gob.es/cima/dochtml/ft/79067/FichaTecnica\\_79067.html](https://www.aemps.gob.es/cima/dochtml/ft/79067/FichaTecnica_79067.html)
- Ficha Técnica Sandimmun Neoral 100mg cápsulas blandas [internet] 2015 [cited 2016 Dec 15]. Available from: [https://www.aemps.gob.es/cima/dochtml/ft/60320/FichaTecnica\\_60320.html](https://www.aemps.gob.es/cima/dochtml/ft/60320/FichaTecnica_60320.html)
- Anexo I. Ficha técnica o resumen de las características del producto. CellCept 250. [internet] [cited 2016 Dec 15]. Available from: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/000082/WC500021864.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000082/WC500021864.pdf)
- Ficha técnica Metotrexato 2,5 mg comprimidos. [internet] 2015 [cited 2016 Dec 15]. Available from: [https://www.aemps.gob.es/cima/dochtml/ft/79758/FichaTecnica\\_79758.html](https://www.aemps.gob.es/cima/dochtml/ft/79758/FichaTecnica_79758.html)
- Bangert CA, Costner MI. Methotrexate in dermatology. *Dermatol Ther.* 2007;20:216–28.
- Carretero G, Puig L, Dehesa L, Carrascosa JM, Ribera M, Sánchez-Regaña M, et al. Metotrexato: guía de uso en psoriasis. *Actas Dermosifiliogr.* 2010;101:600–13.
- Puig L. Metotrexato: novedades terapéuticas. *Actas Dermosifiliogr.* 2014;105:583–9.
- Warren RB, Weatherhead SC, Smith CH, Exton LS, Mohd Mustapa MF, Kirby B, et al. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. *Br J Dermatol.* 2016;175:23–44.
- Gürçan HM, Razzaque Ahmed A. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. *Br J Dermatol.* 2009;161:723–31.
- Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. *Br J Dermatol.* 2007;156:346–51.
- Royer M, Bodemer C, Vabres P, Pajot C, Barbarot S, Paul C, et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata: Efficacy and tolerability of methotrexate in severe childhood AA. *Br J Dermatol.* 2011;165:407–10.
- Perez A, Woods A, Grattan CEH. Methotrexate: A useful steroid-sparing agent in recalcitrant chronic urticaria. *Br J Dermatol.* 2010;162:191–4.
- Wenzel J, Braehler S, Bauer R, Bieber T, Tuting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: Results of a retrospective study in 43 patients. *Br J Dermatol.* 2005;153:157–62.
- Garza-Mayers AC, McClurkin M, Smith GP. Review of treatment for discoid lupus erythematosus. *Dermatol Ther.* 2016;29:274–83.
- Bruijn MS, Horváth B, van Voorst Vader PC, Willemze R, Vermeer MH. Recommendations for treatment of lymphomatoid papulosis with methotrexate: A report from the Dutch Cutaneous Lymphoma Group. *Br J Dermatol.* 2015;173:1319–22.
- Martorell-Calatayud A, Requena C, Nagore E, Sanmartín O, Serra-Guillén C, Botella-Estrada R, et al. Ensayo clínico: la infiltración intralesional con metotrexato de forma neoadyuvante en la cirugía del queratoacantoma permite obtener mejores resultados estéticos y funcionales. *Actas Dermosifiliogr.* 2011;102:605–15.
- Carrascosa JM, de la Cueva P, Ara M, Puig L, Bordas X, Carretero G, et al. Metotrexato en psoriasis moderada-grave: revisión de la literatura y recomendaciones de experto. *Actas Dermosifiliogr.* 2016;107:194–206.
- Carretero-Hernández G. Metotrexato en psoriasis: ¿es necesaria una dosis de prueba? *Actas Dermosifiliogr.* 2012;103:1–4.
- Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: A systematic review. *Br J Dermatol.* 2009;160:622–8.
- Maybury CM, Jabbar-Lopez ZK, Wong T, Dhillon AP, Barker JN, Smith CH. Methotrexate and liver fibrosis in people with psoriasis: A systematic review of observational studies. *Br J Dermatol.* 2014;171:17–29.
- Martyn-Simmons CL, Rosenberg WMC, Cross R, Wong T, Smith CH, Barker JNWN. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: A retrospective cohort study. *Br J Dermatol.* 2014;171:267–73.
- Maybury CM, Samarasekera E, Douiri A, Barker JN, Smith CH. Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: A systematic review and meta-analysis. *Br J Dermatol.* 2014;170:1237–47.
- Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of Stevens-Johnson syndrome/toxic epidermal

- necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. *J Am Acad Dermatol.* 2014;71:941–7.
33. Mirmirani P, Willey A, Price VH. Short course of oral cyclosporine in lichen planopilaris. *J Am Acad Dermatol.* 2003;49:667–71.
  34. Capella GL, Casa-Alberighi OD, Finzi AF. Therapeutic concepts in clinical dermatology: Cyclosporine A in immunomediated and other dermatoses. *Int J Dermatol.* 2001;40:551–61.
  35. Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: Part I. *J Am Acad Dermatol.* 2010;63:925–46.
  36. Mrowietz U, Klein CE, Reich K, Rosenbach T, Ruzicka T, Sebastian M, et al. Cyclosporine therapy in dermatology. *J Dtsch Dermatol Ges.* 2009;7:474–8.
  37. Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: Part II. *J Am Acad Dermatol.* 2010;63:949–72.
  38. Umezawa Y, Mabuchi T, Ozawa A. Preprandial vs postprandial pharmacokinetics of cyclosporine in patients with psoriasis. *Int J Dermatol.* 2007;46:880–2.
  39. Conde-Fernandes I, Torres T, Selores M. Maintenance treatment of psoriasis with cyclosporine A: Comparison between continuous and weekend therapy. *J Am Acad Dermatol.* 2013;68:341–2.
  40. Garrido Colmenero C, Blasco Morente G, Tercedor Sánchez J. Oral cyclosporine weekend therapy: A new maintenance therapeutic option in patients with severe atopic dermatitis. *Pediatr Dermatol.* 2015;32:551–2.
  41. Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011: Guidelines for prescribing azathioprine. *Br J Dermatol.* 2011;165:711–34.
  42. Perrett CM, Walker SL, O'Donovan P, Warwick J, Harwood CA, Karran P, et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. *Br J Dermatol.* 2008;159:198–204.
  43. Martel RM, Melwani P, Islas D, Peñate Y, Borrego L. Seguridad de azatioprina según los niveles de tiopurina metiltransferasa en el tratamiento de la dermatitis atópica infantil. Experiencia en 7 casos. *Actas Dermosifiliogr.* 2010;101:415–20.
  44. Vestergaard T, Bygum A. An audit of thiopurine methyltransferase genotyping and phenotyping before intended azathioprine treatment for dermatological conditions. *Clin Exp Dermatol.* 2010;35:140–4.
  45. Wise M, Callen JP. Azathioprine: A guide for the management of dermatology patients. *Dermatol Ther.* 2007;20:206–15.
  46. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. *Br J Dermatol.* 2002;147:308–15.
  47. Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: Clinical response and thiopurine monitoring. *J Am Acad Dermatol.* 2013;68:29–35.
  48. Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil: Systemic treatment of pediatric atopic dermatitis. *Pediatr Dermatol.* 2011;28:689–94.
  49. Thomsen SF, Karlsmark T, Clemmensen KKB, Graversgaard C, Ibler KS, Jemec GBE, et al. Outcome of treatment with azathioprine in severe atopic dermatitis: A 5-year retrospective study of adult outpatients. *Br J Dermatol.* 2015;172:1122–4.
  50. Patel AA, Swertlick RA, McCall CO. Azathioprine in dermatology: The past, the present, and the future. *J Am Acad Dermatol.* 2006;55:369–89.
  51. Vañó-Galván S, Hermosa-Gelbard Á, Sánchez-Neila N, Miguel-Gómez L, Saceda-Corralo D, Rodrigues-Barata R, et al. Pulse corticosteroid therapy with oral dexamethasone for the treatment of adult alopecia totalis and universalis. *J Am Acad Dermatol.* 2016;74:1005–7.
  52. Liu Y-P, Xu H-Q, Li M, Yang X, Yu S, Fu W-L, et al. Association between thiopurine s-methyltransferase polymorphisms and azathioprine-induced adverse drug reactions in patients with autoimmune diseases: A meta-analysis. *PLoS One.* 2015;10:e0144234.
  53. Liu H, Ding L, Zhang F, Zhang Y, Gao X, Hu P, et al. The impact of glutathione S-transferase genotype and phenotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases. *J Pharmacol Sci.* 2015;129:95–100.
  54. Belgi G, Friedmann PS. Traditional therapies: Glucocorticoids, azathioprine, methotrexate, hydroxyurea. *Clin Exp Dermatol.* 2002;27:546–54.
  55. Fuggle NR, Bragoli W, Mahto A, Glover M, Martinez AE, Kinsler VA. The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring. *J Am Acad Dermatol.* 2015;72:108–14.
  56. Ballester I, Silvestre JF, Pérez-Crespo M, Lucas A. Tratamiento de la dermatitis atópica grave del adulto con mofetil micofenolato en 8 pacientes. *Actas Dermosifiliogr.* 2009;100:883–7.
  57. Frieling U, Luger TA. Mycophenolate mofetil and leflunomide: Promising compounds for the treatment of skin diseases. *Clin Exp Dermatol.* 2002;27:562–70.
  58. Li J, Chong AH, Green J, Kelly R, Baker C. Mycophenolate use in dermatology: A clinical audit: Mycophenolate audit. *Australas J Dermatol.* 2013;54:296–302.
  59. van Velsen SGA, Haeck IM, Bruijnzeel-Koomen CAFM, de Bruin-Weller MS. First experience with enteric-coated mycophenolate sodium (Myfortic®) in severe recalcitrant adult atopic dermatitis: An open label study. *Br J Dermatol.* 2009;160:687–91.
  60. Haeck IM, Knol MJ, Ten Berge O, van Velsen SGA, de Bruin-Weller MS, Bruijnzeel-Koomen CAFM. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trial. *J Am Acad Dermatol.* 2011;64:1074–84.
  61. Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: Experience in 14 patients. *Br J Dermatol.* 2007;157:127–32.
  62. Powell AM, Albert S, Al Fares S, Harman KE, Setterfield J, Bhogal B, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. *Br J Dermatol.* 2003;149:138–45.
  63. Zwerner J, Fiorentino D. Mycophenolate mofetil. *Dermatol Ther.* 2007;20:229–38.
  64. Orvis AK, Wesson SK, Breza TS, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. *J Am Acad Dermatol.* 2009;60:183–99.
  65. Zimmerman AB, Berger EM, Elmariah SB, Soter NA. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: Experience in 19 patients. *J Am Acad Dermatol.* 2012;66:767–70.
  66. Daudén E, Sánchez-Peinado C, Ruiz-Genao D, García-F-Villa M, Onate MJ, García-Díez A. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. *Br J Dermatol.* 2004;150:132–5.
  67. Akhyani M, Chams-Davatchi C, Hemami M, Fateh S. Efficacy and safety of mycophenolate mofetil vs methotrexate for the treatment of chronic plaque psoriasis: MMF vs MTX for psoriasis treatment. *J Eur Acad Dermatol Venereol.* 2010;24:1447–51.
  68. Sokumbi O, el-Azhary RA, Langman LJ. Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases. *J Am Acad Dermatol.* 2013;68:36–40.
  69. Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer. *J Am Acad Dermatol.* 2014;71:203.e1–12.
  70. Gual A, Iranzo P, Mascaró JM Jr. Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: A case series of 20 patients. *J Eur Acad Dermatol Venereol.* 2014;28:814–8.
  71. Kim J, Chan JJ. Cyclophosphamide in dermatology: Cyclophosphamide in dermatology. *Australas J Dermatol.* 2017;58:5–17.

72. De Groot K, Harper L, Jayne DR, Suarez LFF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis: a randomized trial. *Ann Intern Med.* 2009;150:670–80.
73. Cummins DL, Mimouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. *J Am Acad Dermatol.* 2003;49:276–80.
74. Nousari CH, Brodsky R, Anhalt GJ. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. *J Am Acad Dermatol.* 2003;49:148–50.
75. Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. *J Am Acad Dermatol.* 2000;43:1065–9.
76. Sharma VK, Khandpur S. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris. *Clin Exp Dermatol.* 2013;38:659–64.
77. España A, Panizo C, Fernández S, Marquina M, Pretel M, Aguado L, et al. Remisión clínica completa prolongada en pacientes con pénfigo vulgar grave después del tratamiento con ciclos intravenosos de ciclofosfamida. *Actas Dermosifiliogr.* 2009;100:113–20.